Peptides for Weight Loss in Australia: A Category Overview

Short answer

When people search for peptides for weight loss in Australia, they are usually referring to a broad group of compounds studied in metabolic research for their effects on appetite signalling, insulin response and energy balance. This group includes GLP-1 receptor agonists, dual and triple incretin agonists, amylin analogues and growth-hormone-axis compounds. These are scientifically distinct classes, not a single product.

The regulatory picture is mixed and must be read carefully. Some GLP-1 medicines, such as semaglutide and tirzepatide, are registered prescription medicines in Australia for specific indications. Other compounds in the wider research category, such as retatrutide, survodutide and cagrilintide, are investigational and are not on the Australian Register of Therapeutic Goods. None of these should be read as approved for over-the-counter weight management.

What this category actually refers to

The phrase peptides for weight loss is a search-driven label rather than a precise scientific category. In the research literature, the compounds people associate with this phrase are grouped by the biological receptor systems they engage. Understanding those groupings is more useful than treating all of them as interchangeable, because their mechanisms, trial stages and legal status differ substantially.

Below, each class is described at a high scientific level. The focus is on what receptor pathway the compound is reported to act on and roughly where it sits in the research or regulatory pipeline. No human outcome figures are presented here as expectations, and nothing on this page should be read as a therapeutic or efficacy claim.

GLP-1 receptor agonists

GLP-1 receptor agonists mimic glucagon-like peptide-1, an incretin hormone involved in blood-glucose regulation and satiety signalling. Semaglutide is the most widely known example. In Australia, semaglutide is a registered prescription medicine, sold under brand names including Ozempic and Wegovy, for specified indications, and tirzepatide, discussed below as a dual agonist, is similarly a registered prescription medicine.

It is important to separate the pharmacology from the regulatory status. A GLP-1 compound studied in a laboratory context is the same molecule class, but the approved prescription products are finished medicines dispensed under medical supervision. Research-grade material is not a substitute for a prescription medicine and carries a different legal and quality framework entirely.

Dual and triple incretin agonists

A newer line of research combines action on more than one incretin receptor. Dual agonists engage both the GLP-1 and GIP receptors; triple agonists add activity at the glucagon receptor as well. The theory under investigation is that engaging multiple pathways at once may influence appetite and metabolic signalling differently from a single-receptor compound.

Compounds commonly discussed in this class

• Tirzepatide, a GLP-1 and GIP dual agonist, which in Australia is a registered prescription medicine sold under a brand name for specified indications
• Retatrutide, a GLP-1, GIP and glucagon triple agonist, which is investigational and reported to be in late-stage clinical trials and is not on the Australian Register of Therapeutic Goods
• Survodutide, a GLP-1 and glucagon dual agonist, which is investigational and reported to be in ongoing clinical trials and is not on the Australian Register of Therapeutic Goods

The distinction matters legally. Tirzepatide is an approved prescription medicine, whereas retatrutide and survodutide are unapproved research compounds that have not completed the regulatory process in Australia. Grouping them together under one search phrase can obscure this, so each is best understood on its own terms.

Amylin analogues

Amylin is a hormone co-secreted with insulin that is studied for its role in satiety and gastric emptying. Amylin analogues act on a different pathway from the incretin system, which is why they appear in research combinations alongside GLP-1 compounds rather than as straight replacements for them.

Cagrilintide is the amylin analogue most often referenced in current literature. It is investigational and is not on the Australian Register of Therapeutic Goods. It appears in research both as a standalone candidate and in combination studies with incretin agonists. As with every compound on this page, that status describes research activity, not an approval for human use.

Growth-hormone-axis compounds

A separate group of compounds acts on the growth-hormone axis rather than the incretin or amylin systems. These are studied for effects on body composition and lipid metabolism through different mechanisms. Tesamorelin, a growth-hormone-releasing-hormone analogue, and the fragment AOD-9604 are examples that appear in metabolic research discussions.

These compounds are mechanistically distinct from the appetite-signalling incretin class and should not be assumed to behave the same way. Their regulatory position in Australia varies by compound and indication, and where a specific status is uncertain it should be checked against current Therapeutic Goods Administration records rather than assumed.

Australian regulatory status at a glance

The single most important point for anyone researching this category in Australia is that these compounds do not share one status. It is accurate to describe three broad buckets, and conflating them is the most common error in consumer discussion.

Three distinct regulatory buckets

• Registered prescription medicine: approved and entered on the Australian Register of Therapeutic Goods for specified indications and available only on prescription, for example semaglutide and tirzepatide
• Unapproved research compound: a molecule studied in trials but not registered for general supply, which cannot be lawfully sold as a therapeutic good for human use
• Not on the ARTG: the compound does not appear on the Australian Register of Therapeutic Goods at all, which is the case for several investigational agents such as retatrutide, survodutide and cagrilintide

None of the compounds in this category are approved for over-the-counter weight management in Australia. Where a product is a registered prescription medicine, it is accessed through a prescriber. Where a compound is investigational, it sits outside the approved supply chain for human use entirely and belongs to the research setting. If you are unsure about the status of a specific compound, treat that uncertainty as a reason to check current records, not a reason to assume.

How NovaPeptides fits in

NovaPeptides supplies listed compounds strictly for laboratory research use only. Nothing offered is sold, labelled or described for human consumption, and no page on this site provides dosing, protocols or claims about weight-loss results. This category hub exists to organise the science and the regulatory context so that researchers can understand how the classes differ before reading the individual compound guides.

Frequently asked questions